Shares of health-care companies slipped, caught up in a wave of risk aversion that began in the tech sector.
The iShares Nasdaq Biotech index fell roughly 2%--for its biggest decline in a month--as traders dumped high-risk biotech shares.
Continue Reading Below
Shares of British drug giant AstraZeneca plunged after one of its immuno-oncology drugs failed to help patients fight off cancer in a clinical trial.
Shares of Bristol Myers Squibb, another drug maker who has put a lot of resources into its immuno-oncology program, declined even after it posted earnings ahead of Wall Street targets.
-By Rob Curran, firstname.lastname@example.org
(END) Dow Jones Newswires
July 27, 2017 17:14 ET (21:14 GMT)